8 [3] G. Carpenter and S. Cohen, “Epidermal growth factor,” The Journal of Biological Chemistry, vol. 265, no. 14, pp. 7709– 7712, 1990. [4] F. Loupakis, L. Pollina, I. Stasi et al., “PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of beneﬁt from cetuximab plus irinotecan for patients with metastatic colorectal cancer,” Journal of Clinical Oncology, vol. 27, no. 16, pp. 2622–2629, 2009. [5] A. Citri and Y. Yarden, “EGF-ERBB signalling: towards the systems level,” Nature Reviews Molecular Cell Biology, vol. 7, no. 7, pp. 505–516, 2006. [6] N. E. Hynes and H. A. Lane, “ERBB receptors and cancer: the complexity of targeted inhibitors,” Nature Reviews Cancer, vol. 5, no. 5, pp. 341–354, 2005. [7] J. Downward, Y. Yarden, E. Mayes et al., “Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences,” Nature, vol. 307, no. 5951, pp. 521–527, 1984. [8] F. X. Real, W. J. Rettig, and P. G. Chesa, “Expression of epidermal growth factor receptor in human cultured cells and tissues: relationship to cell lineage and stage of diﬀerentiation,” Cancer Research, vol. 46, no. 9, pp. 4726– 4731, 1986. [9] NCCN Clinical Practice Guidelines in Oncology. Colon Cancer, vol. 3, NCCN, Gaithersburg, Md, USA, 2010. [10] C. M. Croce, “Oncogenes and cancer,” The New England Journal of Medicine, vol. 358, no. 5, pp. 502–511, 2008. [11] N. Normanno, C. Bianco, A. De Luca, M. R. Maiello, and D. S. Salomon, “Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment,” Endocrine-Related Cancer, vol. 10, no. 1, pp. 1–21, 2003. [12] L. B. Saltz, N. J. Meropol, P. J. Loehrer, M. N. Needle, J. Kopit, and R. J. Mayer, “Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor,” Journal of Clinical Oncology, vol. 22, no. 7, pp. 1201–1208, 2004. [13] D. Cunningham, Y. Humblet, S. Siena et al., “Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan- refractory metastatic colorectal cancer,” The New England Journal of Medicine, vol. 351, no. 4, pp. 337–345, 2004. [14] H. J. Lenz, E. Van Cutsem, S. Khambata-Ford et al., “Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinote- can, oxaliplatin, and ﬂuoropyrimidines,” Journal of Clinical Oncology, vol. 24, no. 30, pp. 4914–4921, 2006. [15] G. Folprecht, M. P. Lutz, P. Scho¨ﬀski et al., “Cetuximab and irinotecan/5-ﬂuorouracil/folinic acid is a safe combination for the ﬁrst-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma,” Annals of Oncology, vol. 17, no. 3, pp. 450–456, 2006. [16] D. J. Jonker, C. J. O’Callaghan, C. S. Karapetis et al., “Cetuximab for the treatment of colorectal cancer,” The New England Journal of Medicine, vol. 357, no. 20, pp. 2040–2048, 2007. [17] J. Tabernero, E. Van Cutsem, E. Dı´az-Rubio et al., “Phase II trial of cetuximab in combination with ﬂuorouracil, leucovorin, and oxaliplatin in the ﬁrst-line treatment of metastatic colorectal cancer,” Journal of Clinical Oncology, vol. 25, no. 33, pp. 5225–5232, 2007. [18] A. F. Sobrero, J. Maurel, L. Fehrenbacher et al., “EPIC: phase III trial of cetuximab plus irinotecan after ﬂuoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer,” Journal of Clinical Oncology, vol. 26, no. 14, pp. 2311– 2319, 2008. Pathology Research International [19] E. Van Cutsem, M. Nowacki, I. Lang et al., “Randomized phase III study of irinotecan and 5-FU/FA with or with- out cetuximab in the ﬁrst-line treatment of patients with metastatic colorectal cancer (mCRC): the CRYSTAL trial,” Journal of Clinical Oncology, vol. 25, no. 18, supplement, p. 164s, 2007. [20] E. Van Cutsem, M. Peeters, S. Siena et al., “Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer,” Jour- nal of Clinical Oncology, vol. 25, no. 13, pp. 1658–1664, 2007. [21] L. B. Saltz, H. J. Lenz, H. L. Kindler et al., “Randomized phase II trial of cetuximab, bevacizumab, and irinotecan com- pared with cetuximab and bevacizumab alone in irinotecan- refractory colorectal cancer: the BOND-2 study,” Journal of Clinical Oncology, vol. 25, no. 29, pp. 4557–4561, 2007. [22] N. H. Segal, D. Reidy-Lagunes, M. Capanu et al., “Phase II study of bevacizumab in combination with cetuximab plus irinotecan in irinotecan-refractory colorectal cancer (CRC) patients who have progressed on a bevacizumab- containing regimen (The BOND 2.5 Study),” Journal of Clinical Oncology, vol. 27, no. 15, supplement, 2009, ASCO Annual Meeting, abstract no. 4087. [23] M. Malumbres and M. Barbacid, “RAS oncogenes: the ﬁrst 30 years,” Nature Reviews Cancer, vol. 3, no. 6, pp. 459–465, 2003. [24] R. G. Amado, M. Wolf, M. Peeters et al., “Wild-type KRAS is required for panitumumab eﬃcacy in patients with metastatic colorectal cancer,” Journal of Clinical Oncology, vol. 26, no. 10, pp. 1626–1634, 2008. [25] C. J. Allegra, J. M. Jessup, M. R. Somerﬁeld et al., “American society of clinical oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy,” Jour- nal of Clinical Oncology, vol. 27, no. 12, pp. 2091–2096, 2009. [26] W. De Roock, B. Claes, D. Bernasconi et al., “Eﬀects of KRAS, BRAF, NRAS, and PIK3CA mutations on the eﬃcacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis,” The Lancet Oncology, vol. 11, no. 8, pp. 753–762, 2010. [27] J. Baselga and N. Rosen, “Determinants of RASistance to anti-epidermal growth factor receptor agents,” Journal of Clinical Oncology, vol. 26, no. 10, pp. 1582–1584, 2008. [28] S. Khambata-Ford, C. R. Garrett, N. J. Meropol et al., “Expression of epiregulin and amphiregulin and K-ras muta- tion status predict disease control in metastatic colorectal cancer patients treated with cetuximab,” Journal of Clinical Oncology, vol. 25, no. 22, pp. 3230–3237, 2007. [29] W. De Roock, H. Piessevaux, J. De Schutter et al., “KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab,” Annals of Oncology, vol. 19, no. 3, pp. 508– 515, 2008. [30] C. J. Punt, J. Tol, C. J. Rodenburg et al., “Randomized phase III study of capecitabine, oxaliplatin, and bevacizumab with or without cetuximab in advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group,” Journal of Clinical Oncology, vol. 26, supplement, 2008, abstract LBA 4011. [31] C. Bokemeyer, I. Bondarenko, A. Makhson et al., “Flu- orouracil, leucovorin, and oxaliplatin with and without cetuximab in the ﬁrst-line treatment of metastatic colorectal